Enoxaparin Versus Unfractionated Heparin in PCI

Triemli Hospital

Status and phase: Completed; Phase 4

Conditions: Coronary Artery Disease

Treatments: Drug: unfractionated heparin; Drug: Enoxaparin i.v.

Study type: Interventional

Funder types: Other

Identifiers

NCT00439855

ZEUS

Details and patient eligibility

About

Enoxaparin 0.75mg/kg BW is not inferior to weight adjusted unfractionated heparin as anticoagulation for PCI

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• PCI for stable ischemia or ACS

Exclusion criteria

• Cardiogenic shock,
• Pretreatment with study drugs,
• Lack of informed consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)